RE:RE:RE:RE:RE:RE:RE:price actionI thought there was a lots of positives that came out of the cc, even if we didnt get the sales numbers we wanted. The biggest for me was that they'd talked to 2000 doctors (40% of their target 5000 KOL) and the insight from this is that the potential seen in last years marketing research still holds strong.
As JFM lays out here the complexity of the system is delaying that potential turning into sales atm but at some point that will end. In fact the other great part of the cc was that many of the obstacles are well on the way to being dismantled. There is no reason to lower our expectations of the final outcome just patience as the process works through. I think I always believed this would be something of a rollercoaster ride in the first year, I'd somewhat forgotten that as the launch unfolded with a string of positive news.
jfm1330 wrote: This reminds me of the big drop during the Egrifta approval process when some investors sold in panic mode after a press release from the FDA. Those who sold did not understand what it meant and the FDA process with advisory comitees. Now it seems that some are not understanding the process of launching an intrveinous drug in the US in a niche market. They don't understand the insurance process and the doctors behavior. Even though the info about that is out there and clear, fear is at play. They don't undurstand that this is the usual ramping up curve for such a drug. A hockey stick curve and that we are just in the blade part of the hockey stick. The shaft part should start et the begining of September. So even in October results won't be spectacular. We already know that, but they fear or don't have the patience to wait. Usual stuff in this story. Nothing new. We saw that before. The story is unchanged. Potential is still awesome.